Gene-Editing shot aims to slash dangerous fat levels in blood
NCT ID NCT07657780
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a new gene-editing treatment called CS-121 in 15 adults with severe high triglycerides (a type of fat in the blood) that hasn't been controlled by standard treatments. The therapy uses tiny fat particles to deliver a gene editor that targets the APOC3 gene in the liver, aiming to lower fat levels. The main goal is to check safety and side effects, while also seeing if it reduces triglycerides and related proteins.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CS-121 (a gene-editing therapy delivered by lipid nanoparticles to edit the APOC3 gene)
- What this could lead to
- If it works, this could point toward a one-time treatment that controls severe high triglycerides by editing a gene, potentially reducing the need for daily medication.
- What could go wrong
- This is a very early, small trial (15 people) focused on safety, not yet on effectiveness. The therapy is new and may not work as hoped, and there are unknown risks from gene editing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE HYPERTRIGLYCERIDEMIA (SHTG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.